JonesResearch raised the firm’s price target on Praxis Precision (PRAX) to $441 from $83 and keeps a Buy rating on the shares. The company announced positive results for the Phase III Essential3 program of ulixacaltamide in essential tremor, the analyst tells investors in a research note. The firm sees potential for “rapid uptake” of the drug given the limited treatment options available to patients. Ulixacaltamide can reach blockbuster status in 2028, assuming approval in Q1 of 2027, with sales “conservatively estimated” at $12.2B in 2032, contends JonesResearch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Promising Potential of Praxis Precision Medicines: Buy Rating on Ulixacaltamide’s Strong Phase 3 Results and Market Opportunity
- Praxis Precision price target raised to $232 from $115 at H.C. Wainwright
- Praxis Precision price target raised to $250 from $115 at Oppenheimer
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Praxis Precision price target raised to $251 from $61 at TD Cowen